Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Rare Gastrointestinal Diseases Treatment Market Over The Five-Year Period 2025–2029?
The rare gastrointestinal diseases treatment market has experienced significant expansion over recent years. It is anticipated to increase from $1.36 billion in 2024 to $1.45 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.1%. The historical expansion of this market can be attributed to the growing number of patient advocacy initiatives, an increase in clinical trials for rare gastrointestinal (GI) therapies, improved early diagnosis through advanced screening, enhanced collaboration between pharmaceutical entities and research institutes, and a heightened demand for targeted treatment alternatives.
The market for treating rare gastrointestinal diseases is anticipated to experience substantial growth over the coming years, with projections indicating it will reach $1.81 billion by 2029, expanding at a compound annual growth rate (CAGR) of 5.7%. This expansion during the forecast period is primarily driven by heightened investment in the development of novel drugs, increasing adoption of personalized medicine, the broadening application of precision medicine, improved awareness and education among healthcare professionals, and the growing establishment of rare disease patient registries. Prominent trends expected in this period include advancements in genomic and molecular diagnostics, the evolution of targeted biologic therapies, innovations in drug delivery systems, progress in telehealth and remote patient monitoring, and the creation of artificial intelligence (AI)-driven clinical decision support tools.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28317&type=smp
What Are The Key Drivers Of Growth In The Rare Gastrointestinal Diseases Treatment Market?
The increasing prevalence of diagnostic testing is anticipated to drive the expansion of the rare gastrointestinal diseases treatment market moving forward. Diagnostic tests are medical procedures carried out to identify, diagnose, or monitor various diseases, conditions, or infections in patients. The heightened demand for these tests primarily arises from increased awareness about the critical role of early disease detection, which facilitates timely interventions and ultimately leads to better patient outcomes. Specifically for rare gastrointestinal diseases, diagnostic testing supports treatment by enabling the early and accurate identification of underlying health issues. It helps in determining specific disease pathways, assisting in the creation of personalized treatment plans, and improving patient prognoses through opportune medical intervention. For instance, in December 2024, data from the National Health Service, a UK-based government department, indicated that the number of diagnostic tests by activity reached 2,544,809 in 2024, marking an increase from 2,312,030 in 2023. This demonstrates how the surge in diagnostic testing is fueling the growth of the rare gastrointestinal diseases treatment market.
What Are The Segment Types Shaping The Rare Gastrointestinal Diseases Treatment Market?
The rare gastrointestinal diseases treatment market covered in this report is segmented as
1) By Type: Drugs, Device
2) By Route Of Administration: Oral, Intravenous (IV) Or Injectable, Subcutaneous, Other Routes Of Administration
3) By Application: Eosinophilic Gastroenteritis, Hercksprung’s Disease, Chronic Intestinal Pseudo-Obstruction
4) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Drugs: Anti-Inflammatory Drugs, Immunosuppressive Agents, Biologic Therapies, Antibiotics, Proton Pump Inhibitors, Corticosteroids, Enzyme Replacement Therapies
2) By Devices: Endoscopic Devices, Diagnostic Imaging Systems, Surgical Instruments, Feeding Tubes, Stent Devices, Biopsy Devices
What Long-Term Trends Will Shape The Future Growth Of The Rare Gastrointestinal Diseases Treatment Industry?
Leading companies within the rare gastrointestinal diseases treatment market are focusing on developing innovative treatments, such as fully human monoclonal antibodies, to target disease pathways and improve patient outcomes. These fully human monoclonal antibodies are laboratory-engineered antibodies made entirely from human proteins that specifically target disease-causing molecules, helping to precisely block or modulate them and enhance treatment effectiveness while reducing side effects. For instance, in August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for Veopoz (pozelimab-bbfg) for CHAPLE disease, a rare and life-threatening hereditary gastrointestinal disorder. Veopoz is a fully human monoclonal antibody designed to target complement factor C5, helping to regulate the overactive complement system that causes protein loss and gastrointestinal damage in patients with CHAPLE. This targeted mechanism of action addresses the underlying cause of the disease, preventing debilitating symptoms and potentially life-threatening complications.
Who Are The Primary Competitors In The Global Rare Gastrointestinal Diseases Treatment Market?
Major companies operating in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., and Ellodi Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
How Is Rare Gastrointestinal Diseases Treatment Market Demand Varying Across Different Regions?
North America was the largest region in the rare gastrointestinal diseases treatment market in 2024. The regions covered in rare gastrointestinal diseases treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Rare Gastrointestinal Diseases Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28317&type=smp
Browse Through More Reports Similar to the Global Rare Gastrointestinal Diseases Treatment Market 2025, By The Business Research Company
Rare Diseases Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Rare Inflammatory Disease Treatment Global Market Report 2025
Gastrointestinal Drug Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model